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Chemical-genetic disruption of clathrin function 
spares adaptor complex 3–dependent endosome 
vesicle biogenesis
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Andrew A. Pedend, and Victor Faundeza
aDepartment of Cell Biology, bDivision of Cardiology, Department of Medicine, and cIntegrated Cellular Imaging 
Microscopy Core, Emory University, Atlanta, GA 30322; dDepartment of Biomedical Science, University of Sheffield, 
Sheffield S10 2TN, United Kingdom
ABSTRACT A role for clathrin in AP-3–dependent vesicle biogenesis has been inferred from 
biochemical interactions and colocalization between this adaptor and clathrin. The functional-
ity of these molecular associations, however, is controversial. We comprehensively explore 
the role of clathrin in AP-3–dependent vesicle budding, using rapid chemical-genetic pertur-
bation of clathrin function with a clathrin light chain–FKBP chimera oligomerizable by the 
drug AP20187. We find that AP-3 interacts and colocalizes with endogenous and recombi-
nant FKBP chimeric clathrin polypeptides in PC12-cell endosomes. AP-3 displays, however, a 
divergent behavior from AP-1, AP-2, and clathrin chains. AP-3 cofractionates with clathrin-
coated vesicle fractions isolated from PC12 cells even after clathrin function is acutely inhib-
ited by AP20187. We predicted that AP20187 would inhibit AP-3 vesicle formation from 
endosomes after a brefeldin A block. AP-3 vesicle formation continued, however, after brefel-
din A wash-out despite impairment of clathrin function by AP20187. These findings indicate 
that AP-3–clathrin association is dispensable for endosomal AP-3 vesicle budding and sug-
gest that endosomal AP-3–clathrin interactions differ from those by which AP-1 and AP-2 
adaptors productively engage clathrin in vesicle biogenesis.
INTRODUCTION
Exocytic and endocytic compartments exchange components and 
maintain their composition by means of carriers, some of which are 
vesicles (Bonifacino and Glick, 2004; De Matteis and Luini, 2011). 
The generation of vesicles and the selective loading of proteins and 
lipids into them require diverse monomeric and heteromeric cytoso-
lic coats. Among the latter, heterotetrameric adaptor complexes 
AP-1–5 specify distinct trafficking routes. AP-1–5 adaptors comprise 
four subunits of various sizes: two large subunits, B1-5 and A, G, D, E, 
or Z; one medium-size, µ1-5 subunit; and a small, S1-5 subunit. All 
of these heterotetrameric adaptor complexes share the ability to 
recognize specific sorting signals in the cytosolic domains of mem-
brane proteins. Some adaptors have in common the capacity to 
bind phosphoinositides, GTPases, and proteins that act as modules 
to connect a nascent vesicle to diverse machineries. These include, 
but are not limited to, membrane deformation, the cytoskeleton, or 
the recognition of specialized cargoes. In contrast, these adaptor 
complexes differ in their ability to bind clathrin and/or cosediment 
with clathrin-coated vesicles (Kirchhausen, 2000; Bonifacino and 
Traub, 2003; Bonifacino and Glick, 2004; Robinson, 2004; Hirst 
et al., 2011; McMahon and Boucrot, 2011).
Clathrin heavy-chain and the associated clathrin light-chain poly-
peptides assemble into triskelia, which are the structural building 
blocks of clathrin cages. These cages encase and help to concen-
trate adaptors with their bound membrane cargoes and other as-
sociated factors in the transition from a clathrin-coated membrane 
pit into a clathrin-coated vesicle bud. AP-1 and AP-2 bind to the 
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(Dell’Angelica et al., 1998; Blondeau et al., 2004; Borner et al., 2006; 
Salazar et al., 2009). Under knockdown conditions, clathrin vesicle 
formation is impaired, leading to reduced content of proteins copu-
rifying with clathrin-coated vesicles including AP-3 subunits (Borner 
et al., 2006). We revisited these criteria in HEK293 cell and PC12 
cells expressing mCh-FKBP-CLC to validate this recombinant tool. 
We used shRNA-mediated clathrin heavy-chain knockdown in HEK 
cells, followed by clathrin-coated vesicle isolation, to determine 
whether AP-3 adaptor subunits could be considered components of 
clathrin-coated vesicles in cells transiently expressing mCh-FKBP-
CLC. Equal protein loads from control knockdown and clathrin 
heavy-chain down-regulated clathrin-coated vesicle fractions were 
analyzed by SDS–PAGE and Western blot (Figure 1, A and B). Clath-
rin heavy chain was enriched in clathrin-coated vesicle fractions 
(Figure 1A, compare lanes 1 and 3, asterisk), and the content of 
clathrin heavy chain and other fraction polypeptides decreased after 
clathrin heavy-chain down-regulation (Figure 1A, compare lanes 3 
and 4). In addition, mCh-FKBP-CLC and adaptor complexes AP-1–3 
were enriched in clathrin-coated vesicle fractions (Figure 1B, com-
pare lanes 1 and 6), and their presence in clathrin-coated vesicle 
enriched fractions was similarly sensitive to shRNA clathrin heavy-
chain down-regulation (Figure 1B, compare lanes 6 and 12). AP-3 
content in clathrin-coated vesicle enriched fractions was insensitive 
to down-regulation of BLOC-1 complexes, a major AP-3 interactor 
(Supplemental Figure S1; Di Pietro et al., 2006; Salazar et al., 2009; 
Gokhale et al., 2012; Lee et al., 2012). These results are compatible 
with the hypothesis that a subset of clathrin-coated vesicles may 
contain the adaptor complex AP-3.
We further tested the possible association of AP-3 with clathrin 
by coimmunomagnetic precipitations. We performed cross-linking 
with the homo-bifunctional cross-linker dithiobis-succinimidyl pro-
pionate (DSP) in intact cells (Lomant and Fairbanks, 1976; Zlatic 
et al., 2010). Our rationale was to chemically stabilize putative 
clathrin–AP-3 associations in intact cells and use stringent isolation 
conditions to prevent cell-free clathrin–AP-3 associations after cell 
solubilization. mCh-FKBP-CLC HEK293 cells were treated in the 
absence or presence of DSP, and detergent cell extracts were incu-
bated with magnetic beads containing antibody directed against 
clathrin light chain (Figure 1C), clathrin heavy chain (Figure 1D), or 
AP-3 D (Figure 1E). Isolated immunocomplexes were analyzed by 
Western blot. Clathrin light-chain immunocomplexes coisolated 
with both clathrin heavy chain and the AP-3 adaptor subunit B3 
(Figure 1C, lane 3). Similarly, isolation of clathrin heavy-chain im-
munocomplexes precipitated both clathrin light chain and the AP-3 
adaptor subunit B3, the latter only in the presence of DSP cross-
linker (Figure 1D, compare lanes 5 and 6). In addition, the associa-
tion between clathrin chains and AP-3 could be detected in reverse 
magnetic precipitations where AP-3 was isolated with AP-3 D anti-
bodies, which coprecipitated AP-3 B3 and S3 subunits, as well as 
both clathrin chains (Figure 1E). As before, clathrin chains copre-
cipitated with AP-3 only in the presence of cross-linker (Figure 1E, 
compare lanes 5 and 6). These clathrin–AP-3 interactions were also 
detected in PC12 neuroendocrine cells stably expressing mCh-
FKBP-CLC (Figure 1F). We included PC12 cells in our study be-
cause of their extensively characterized AP-3 vesicle biogenesis 
pathway (Faundez et al., 1997, 1998; Faundez and Kelly, 2000; Shi 
et al., 1998). The selectivity of clathrin and AP-3 coprecipitations in 
HEK293 cells and PC12 cells was examined with either control iso-
type-matched antibodies or peptide antigen competition (Figure 
1, C and D, and E and F, respectively). These results suggest that a 
subset of clathrin-coated vesicles contains the adaptor complex 
AP-3 at steady state.
clathrin heavy chain via the appendages of B adaptins (Kirchhausen, 
2000; Bonifacino and Traub, 2003; Bonifacino and Glick, 2004; 
Robinson, 2004; Hirst et al., 2011; McMahon and Boucrot, 2011; 
Willox and Royle, 2012). Extensive biochemical, structural, and func-
tional evidence indicates that clathrin association with AP-1 and 
AP-2 is necessary for vesicle formation by these adaptors 
(Kirchhausen, 2000; Bonifacino and Traub, 2003; Bonifacino and 
Glick, 2004; Robinson, 2004; Hirst et al., 2011; McMahon and 
Boucrot, 2011; Willox and Royle, 2012). In contrast, adaptor com-
plexes AP-4 and AP-5 do not cofractionate with clathrin-coated 
vesicles and may function independently of clathrin, although more 
research on these complexes is needed to establish certainty (Hirst 
et al., 1999, 2013; Borner et al., 2006, 2012). A more thoroughly 
studied adaptor, the AP-3 complex, has a debatable relationship 
with clathrin. A functional equivalence for AP-3 with AP-1 or AP-2 
has been inferred based on biochemical interactions and colocaliza-
tion of AP-3 with clathrin. Nonetheless, the precise functional role of 
clathrin in AP-3 vesicle generation has been a matter of dispute 
since AP-3’s discovery (Dell’Angelica et al., 1997, 1998; Faundez 
et al., 1997, 1998; Shi et al., 1998; Blondeau et al., 2004; Peden 
et al., 2004; Theos et al., 2005; Borner et al., 2006; Salazar et al., 
2009; Kural et al., 2012).
AP-3 generates vesicles that traffic membrane proteins from en-
dosomes to lysosomes, lysosome-related organelles, or synaptic 
vesicles. Defects in this vesicle formation machinery translate into 
the type 2 Hermansky–Pudlak syndrome in humans, a disease that 
shares a similar constellation of phenotypes with AP-3–null mice and 
flies, the most prominent of these being pigment dilution (Wei, 
2006; Wei and Li, 2012; Danglot and Galli, 2007; Newell-Litwa et al., 
2007; Raposo and Marks, 2007; Raposo et al., 2007). In this study, 
we comprehensively explore the role of clathrin in AP-3–dependent 
vesicle budding, using rapid chemical-genetic perturbation of clath-
rin function. We recapitulate key biochemical and colocalization 
findings by others. However, despite a clathrin and AP-3 interaction, 
AP-3–dependent budding from endosomes is resistant to rapid 
clathrin inhibition in whole-cell assays. We propose that the interac-
tion between clathrin and AP-3 at endosomes fulfills functions 
distinct from the canonical role of clathrin in AP-1– and AP-2–
dependent vesicle formation.
RESULTS
We sought to test the function of clathrin interactions with the adap-
tor complex AP-3, using chronic and acute chemical-genetic pertur-
bations of clathrin function. We hypothesized that if AP-3 vesicle 
budding from endosomes requires clathrin, as is the case for AP-1 
and AP-2, then chronic and acute clathrin perturbation should simi-
larly affect the content of these three adaptors in clathrin-coated 
vesicle fractions. We used short hairpin RNA (shRNA) down-regulation 
of clathrin heavy chain as a mean to chronically perturb clathrin. 
Acute interference of clathrin function was achieved with a clathrin 
light-chain chimera carrying in tandem an mCherry tag and an FKBP 
oligomerization domain (mCh-FKBP-CLC). Induction of mCh-FKBP-
CLC quaternary structures impairs clathrin function in minutes after 
addition of the bivalent FKBP-binding agent AP20187 by trapping 
clathrin polypeptides and their associated molecules on membranes 
(Moskowitz et al., 2003; Deborde et al., 2008; Zlatic et al., 2011). 
This rapid onset of effects is in contrast with clathrin heavy-chain 
down-regulation by shRNA, which takes several days to attain clath-
rin function inhibition.
Clathrin and AP-3 interactions have been documented by means 
of in vitro pull-downs with the hinge-ear domain of AP-3 B3 sub-
units, as well as by AP-3 enrichment in clathrin-coated vesicles 
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that mCh-FKBP-CLC occupies nearly all clathrin heavy chain–positive 
structures in HEK293 cells (Zlatic et al., 2011). Similarly, mCh-FKBP-
CLC and clathrin heavy-chain signals extensively overlapped in 
PC12 cells, as revealed by deconvolution microscopy (74 o 8.6% of 
all clathrin heavy-chain pixels present in a cell, n  10; data not 
shown), validating recombinant clathrin light chain as a marker of 
clathrin coats in this neuroendocrine cell. In contrast, only 10–20% 
of all clathrin-positive structures present in a PC12 cell overlapped 
with AP-3 pixels (Figures 2A and 3 and Supplemental Figure S2). 
Structures for which the AP-3 and clathrin overlapped in images 
Our biochemical results suggested a low extent of overlap be-
tween clathrin and AP-3 polypeptides. Our goal was to quantita-
tively assess the extent to which clathrin and AP-3 associate in PC12 
cells expressing mCh-FKBP-CLC at steady state, in particular in early 
endosome compartments. Thus we performed indirect immuno-
fluorescence experiments with high-resolution deconvolution mi-
croscopy or superresolution structured illumination microscopy 
(Figures 2 and 3, Supplemental Figures S2–S4, and Supplemental 
Movie S1). Polypeptides were detected with antibodies against 
AP-3 D, clathrin light chain, or mCherry. We previously demonstrated 
FIGURE 1: Cofractionation and coimmunomagnetic isolation of clathrin and AP-3 in cells expressing mCherry-FKBP-CLC. 
(A) Coomassie stain of homogenate (H) and clathrin-coated vesicle (CCV) fractions from HEK293 cells transiently 
transfected with mCh-FKBP-CLC and infected with either control shRNA (lanes 1 and 3) or shRNA directed against the 
clathrin heavy-chain message (lanes 2 and 4). Asterisk represent clathrin heavy-chain polypeptide. (B) Western blot of 
clathrin-coated vesicle fractionation from A. (C) Western blot of clathrin light-chain (lane 3) and control (lane 2) 
immunomagnetic isolations from HEK293 cells transiently transfected with mCherry-FKBP-CLC. Input represents 5% of 
load. (D) Western blot of clathrin heavy-chain (lanes 5 and 6) and control (lanes 3 and 4) immunomagnetic isolations from 
HEK293 cells transiently transfected with mCh-FKBP-CLC in the absence or presence of the cross-linker DSP. Input 
represents 5% of load. (E) Western blot of AP-3 D (lanes 5 and 6) and AP-3 D with peptide competition (lanes 3 and 4) in 
HEK293 cells transiently transfected with mCh-FKBP-CLC in the absence or presence of the cross-linker DSP. Input 
represents 5% of load. (F) Western blot of AP-3 D (lane 3) and AP-3 D with peptide competition (lane 2) in PC12 cells 
stably transfected with mCh-FKBP-CLC in the presence of the cross-linker DSP. Input represents 1.25% of load. Black 
asterisk indicates CLC signal. Double white asterisks indicate antibody signal. CCV, clathrin-coated vesicle fraction; H, 
homogenate; IB, immunoblot; IP, immunomagnetic isolation;P1, pellet 1; pellet 2; S1, supernatant 1; P2, S2 supernatant 2.
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on endosomes (Figure 3, A, B, and D) rather than an increase of 
AP-3 on these organelles (Figure 3, A, B, and E). We further tested 
the presence of AP-3 and clathrin overlapping domains in endo-
somes by transiently expressing an enhanced green fluorescent 
protein (EGFP)–tagged Rab5 Q79L mutant in PC12 cells stably 
expressing mCh-FKBP-CLC (Supplemental Figures S3 and S4). 
Molecules were detected in fixed cells using antibodies against 
EGFP, mCherry, and AP-3 D. The EGFP-tagged Rab5 Q79L mutant 
allowed us to unequivocally identify early endosomes for quantita-
tive analysis of AP-3 and clathrin subcellular overlap. Rab5 Q79L 
early endosomes were identified by their enlarged EGFP perimeter 
(Supplemental Figure S3). In these endosomes, we determined the 
percentage of their perimeter occupied by either clathrin or AP-3. 
mCh-FKBP-CLC covered 35 o 5.2% of the EGFP-Rab5 Q79L–
labeled perimeter (Supplemental Figure S4A, column 1). Similarly, 
AP-3 was present in 30.5 o 5.9% of the EGFP-labeled endosome 
limiting membrane (Supplemental Figure S4A, column 3), the ex-
tent of which was not significantly modified by the addition of 
AP20187 (Supplemental Figure S4A, column 4). Of importance, a 
fraction of the entire AP-3 signal present in the endosome perimeter 
overlapped with mCh-FKBP-CLC (15.6 o 3.8%; Supplemental 
Figure S4A, column 5). This result is in good agreement with previ-
ous quantitative electron immunomicroscopy data indicating that 
not all AP-3 budding profiles in early endosomes are decorated with 
clathrin in cell types other than PC12 cells (Peden et al., 2004; Theos 
et al., 2005). These results indicate that a pool of AP-3 overlaps with 
clathrin light chain in early endosomes, the site of origin for AP-3 
microvesicles in PC12 cells.
PC12 cells generate clathrin-coated vesicles from the plasma 
membrane by a mechanism that is AP-2 and clathrin dependent yet 
brefeldin A insensitive (Figure 4, step 1). These clathrin-coated ves-
icles feed to early endosomes, where synaptic-like microvesicles 
(SLMVs) bud by a mechanism that instead requires AP-3 and ARF1. 
This AP-3 budding pathway is sensitive to brefeldin A (Figure 4, step 
2; Faundez et al., 1997, 1998; Faundez and Kelly, 2000; Shi et al., 
1998). Synaptic membrane proteins sorted into these SLMVs, such 
as SV2 or VAMP7, sequentially use these two vesicle-generation 
steps, whose vesicle products can be distinguished by their distinc-
tive sedimentation properties (Figure 4). This allows selective isola-
tion of clathrin-coated vesicles and SLMVs. We took advantage of 
features distinguishing these pathways to selectively test the re-
quirement of clathrin in the budding of AP-2 and AP-3 vesicles in 
PC12 cells stably expressing mCh-FKBP-CLC. We first asked whether 
the content of adaptor subunits cosedimenting with clathrin-coated 
vesicles was sensitive to the acute inhibition of clathrin function in 
mCh-FKBP-CLC–expressing PC12 cells. Our hypothesis predicted 
that if AP-3 vesicle budding requires clathrin, then acute clathrin 
perturbation should similarly affect the content of adaptors in clath-
rin-coated vesicle fractions. Stably transfected mCh-FKBP-CLC 
PC12 cells were treated for 2 h with vehicle control or AP20187 to 
perturb clathrin function. We determined the global effectiveness of 
AP20187 treatment by the redistribution of clathrin and AP-3 toward 
the perinuclear area after drug incubation (Supplemental Figure S2), 
the accumulation of clathrin in EEA1-positive endosomes (Figure 3), 
and a reduction in endosome perimeter after drug addition (Supple-
mental Figure S4D, and data not shown; Deborde et al., 2008; Zlatic 
et al., 2011). Clathrin-coated vesicle–enriched fractions were pre-
pared from vehicle and AP20187-treated cells and fraction contents 
analyzed by SDS–PAGE and Western blot (Figure 5A). AP20187 se-
lectively decreased a major polypeptide of ^180 kDa in clathrin-
coated vesicle fractions resolved by SDS–PAGE. We confirmed this 
band as clathrin heavy chain by immunoblot (Figure 5, A and B). 
acquired using deconvolution microscopy were imaged using su-
perresolution structured illumination microscopy (SIM). SIM provides 
a theoretical doubling of spatial resolution above wide-field decon-
volution (^120 nm, x–y; 300 nm, z). Analysis of SIM images showed 
that the overlap of clathrin and AP-3 remained (SIM, Figure 2, B and 
C; Schermelleh et al., 2008).
In the following experiments, we specifically focused on early 
endosomal compartments since these endosomes bud a biochemi-
cally and pharmacologically tractable microvesicle population gen-
erated by an AP-3–dependent mechanism (Faundez et al., 1997, 
1998; Faundez and Kelly, 2000; Clift-O’Grady et al., 1998; Shi et al., 
1998). To examine the subcellular distribution of clathrin and AP-3 
adaptor in endosomes, we determine the extent of AP-3 signal 
overlap with clathrin in endosomes identified with the early endo-
some marker EEA1 (Figure 3). We performed triple indirect immu-
nofluorescence experiments with antibodies against AP-3 D, the 
mCherry tag in mCh-FKBP-CLC, and EEA1 using high-resolution 
deconvolution microscopy. AP-3 and CLC colocalized in early endo-
somes (Figure 3). Moreover, the extent of AP-3–CLC signal overlap 
significantly increased from 20.7 o 7.1% (average o SEM) to 25.9 o 
6.6% after trapping clathrin chains on membranes by the addition of 
AP20187 (Figure 3, A–C). This increased overlap after AP20187 oc-
curred at the expense of an accumulation of clathrin polypeptides 
FIGURE 2: Analysis of clathrin light-chain and AP-3 D colocalization in 
PC12 cells using high-resolution deconvolution microscopy and 
superresolution structured illumination microscopy. (A) High-
resolution deconvolution microscopy done in the Huygens algorithm 
and (B) Superresolution SIM of a single PC12-cell z-plane. Insert, 
threefold enlargement of the boxed region. Arrows direct attention to 
discrete puncta showing colocalization between clathrin light chain 
(CLC) and AP-3 D signals. (C) Isosurface rendering through 10 z-planes 
of SIM microscopy in B. Scale bar, 5 µm. Boxed region includes 
surface reconstruction enlarged in C1 and C2. (C1) Arrows draw 
attention to the same discrete puncta in A and B. Dotted lines outline 
area of colocalization. Scale bar, 0.5 µm. (C2) A 45° rotation of C1 
around a vertical axis. See Supplemental Movie S1.
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suggest, however, that a putative clathrin–
AP-3 interaction differs from other clathrin–
adaptor interactions after acute clathrin 
function perturbation. This differential be-
havior of AP-3 content in clathrin-coated 
vesicle fractions after AP20187 treatment 
raises the question of whether it also reflects 
a differential requirement of clathrin in en-
dosome AP-3 vesicle generation.
To test the function of clathrin interac-
tions with the adaptor complex AP-3, we 
took advantage of PC12 cells expressing 
mCh-FKBP-CLC and the pharmacological 
sensitivity of AP-3 vesicle budding to brefel-
din A. The sequential organization of AP-2 
and AP-3 budding steps has so far pre-
cluded a direct test of clathrin’s role in endo-
some SLMV formation using long-term 
clathrin perturbations such as shRNA or ex-
pression of clathrin heavy-chain recombi-
nant fragments (Figure 4). Therefore we 
used pharmacological epistasis between 
the brefeldin A and AP20187 blocks in 
mCh-FKBP-CLC–expressing PC12 cells to 
selectively assess a role of clathrin in AP-3 
vesicle generation. Brefeldin A completely 
and reversibly inhibits SLMV formation by 
AP-3 while sparing the generation of AP-2 
vesicles (Figure 4, steps 1 and 2; Faundez 
et al., 1997; Shi et al., 1998). If the AP-3 bud-
ding step requires clathrin, we reasoned 
that after a SLMV brefeldin A block, a brefel-
din A washout in the presence of AP20187 
should prevent de novo SLMV generation. 
In contrast, if clathrin is dispensable for AP-3 
vesicle budding, then a brefeldin A washout 
in the presence of AP20187 should lead to a 
complete recovery of SLMV formation. We 
used VAMP7 and SV2 to track SLMV pres-
ence and their formation after pharmaco-
logical blockages. We selected these two 
transmembrane proteins because they are enriched in SLMV and 
mostly localize to endosome compartments at steady state in cells 
of the neural lineage (Newell-Litwa et al., 2009). In addition, VAMP7 
is an AP-3 cargo that directly binds AP-3 (Martinez-Arca et al., 2003; 
Kent et al., 2012). mCh-FKBP-CLC–expressing PC12 cells were incu-
bated in the presence of vehicle or brefeldin A for 2 h, and SLMVs 
were isolated by differential centrifugation followed by glycerol ve-
locity sedimentation. Glycerol velocity gradients resolve SLMVs by 
size as a peak in the middle of the gradient (Figure 6, fractions 8–10; 
Clift-O’Grady et al., 1998). Brefeldin A decreased SLMVs as deter-
mined by VAMP7 and SV2 gradient content (Figure 6, A–C and 
A1–C1, open circles). This brefeldin A block was released after 
brefeldin A washout and incubation of cells in ethanol vehicle con-
trol for additional 2 h (Figure 6, B and B1, black circles). Of note, 
continuous incubation of cells in AP20187 instead of vehicle for 2 h 
had no effect on the reversibility of the brefeldin A washout (Figure 
6, C and C1, black circles). This outcome was not due to either a 
reversal of the brefeldin A block after 4 h of incubation (Supplemen-
tal Figure S5) or a redistribution of mCh-FKBP-CLC chains away from 
endosomes after AP20187. In fact, AP20187 incubation neither 
modified clathrin or AP-3 nor changed AP-3-clathrin light-chain 
Concurrent with clathrin heavy chain depletion, we detected de-
creased content of endogenous clathrin light chain and recombi-
nant mCh-FKBP-CLC in clathrin-coated vesicle–enriched fractions 
(Figure 5C, compare lanes 6 and 12). Of importance, the content of 
AP-1 G adaptin and AP-2 A adaptin were similarly reduced in clath-
rin-coated vesicle fractions isolated from AP20187-treated cells 
(Figure 5, B and C, compare lanes 1 and 2, and 6 and 12, respec-
tively, and D). Clathrin-coated vesicle cargoes synaptobrevin 2, syn-
aptophysin, and VAMP7 (Blondeau et al., 2004; Takamori et al., 
2006) were reduced after AP20187 treatment, a further indication 
that plasma membrane clathrin-coated vesicle formation was im-
paired by mCh-FKBP-CLC oligomerization (Figure 5C, compare lanes 
6 and 12, and D). Strikingly, even though treatment with AP20187 
impaired the formation of AP-1 and AP-2 clathrin-coated vesicles, 
we observed an increase in the levels of AP-3 in clathrin-coated 
vesicle enriched–fractions as determined by immunoblot with anti-
bodies against B3, D, and S3 subunits (Figure 5, B and C, compare 
lanes 1 and 2, and 6 and 12, respectively, and D). These results dem-
onstrate that clathrin-coated vesicle formation by AP-1– and AP-2–
dependent mechanisms is robustly impaired by acute clathrin oli-
gomerization in PC12 cells expressing mCh-FKBP-CLC. Our findings 
FIGURE 3: Analysis of clathrin light-chain and AP-3 D colocalization in PC12-cell early 
endosomes. (A, B) High-resolution deconvolution microscopy of PC12 cells incubated in the 
presence of vehicle or AP20187 and triple labeled with antibodies against AP-3 D, the mCherry 
tag in mCh-FKBP-CLC, and EEA1. Scale bar, 5 µm. (C–E) Probability plots of the extent of pixel 
overlap among marker pairs (Y axis) in cells treated with vehicle (blue traces) and AP20187 (red 
traces). The p values were determined using the Kolmogorov–Smirnov test. Vehicle, n  167 
endosomes from 55 cells acquired from three biological replicates. AP20187, n  203 
endosomes from 68 cells acquired from three biological replicates.
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lanes 1 and 2). These D-S3 polypeptides correspond to the reported 
D-S3 adaptor hemicomplexes described in Ap3b1pe/pe cells (Peden 
et al., 2002). We used the BLOC-1 complex, an AP-3 interactor, and 
overlap in the limiting membrane of enlarged early endosomes 
(Supplemental Figure S4A, compare even and odd columns) over a 
wide range of clathrin content per endosome and endosome size 
(Supplemental Figure S4, B and C). This observation is consistent 
with the described AP20187-dependent trapping of clathrin poly-
peptides on membranes (Moskowitz et al., 2003; Deborde et al., 
2008; Zlatic et al., 2011). These results demonstrate that the bio-
chemical interaction between AP-3 and clathrin chains found in 
PC12 cells is dispensable for the budding of AP-3-derived SLMV 
and are in agreement with the previous contention that AP-3 com-
plexes carrying mutations in the B3 putative clathrin binding domain 
are functional.
The dispensability of clathrin function for AP-3–dependent SLMV 
formation suggests that interactions between AP-3 and clathrin de-
tected in PC12 cells and other cells types may not follow a canonical 
association mechanism between the ear domain of the B subunit of 
the adaptor and clathrin terminal domain (Willox and Royle, 2012). 
To test this hypothesis, we focused on fibroblasts carrying the B3A 
mutation pearl (Ap3b1pe/pe). These cells carry a hypomorphic muta-
tion in the AP-3 complex that affects the sorting of AP-3 cargoes. 
We used Ap3b1pe/pe cells or Ap3b1pe/pe rescued with either recom-
binant wild-type B3A or B3A mutations ablating putative clathrin-
binding determinants (clathrin box) in the B3A hinge-ear domain to 
test whether an AP-3–clathrin interaction is sensitive to mutagenesis 
of the B3 clathrin box. These mutations included discrete changes in 
the B3A clathrin-binding sequence 817SLLDLD822 (B3A817AAA), a 
deletion of the 817SLLDLD822 clathrin box (B3A$807-831), and a trun-
cation of the entire B3A ear domain (B3A807Stop). With the excep-
tion of B3A807Stop, all other B3A clathrin box mutants rescued a 
missorting phenotype in Ap3b1pe/pe cells (Peden et al., 2002). We 
performed DSP cross-linking in intact cells followed by immuno-
magnetic isolation of AP-3 complexes with D antibodies. The D 
adaptin antibodies precipitated S3 subunits from Ap3b1pe/pe and 
notably low levels of clathrin in the presence of DSP but not BLOC-1 
subunits detected with antibodies against pallidin (Figure 7, compare 
FIGURE 5: AP-3 levels increase in clathrin-coated vesicle fractions 
after acute clathrin function perturbation. (A) Coomassie stain of 
SDS–polyacrylamide gel loaded with fractions of CCVs isolated from 
PC12 cells stably expressing mCh-FKBP-CLC. Cells were treated for 
2 h with vehicle (lanes 1–6) or the drug AP20187 to acutely perturb 
clathrin function (lanes 7–12). Arrows direct attention to a band that 
runs consistent with clathrin heavy-chain molecular weight. 
(B) Western blot of CCVs fraction from A. Arrow draws attention to a 
band in clathrin heavy-chain immunoblot that shows a decrease in the 
CCV fraction from cells with acute clathrin perturbation compared 
with vehicle control. Decrease in clathrin signal from CCV fraction of 
drug-treated cells indicates that acute clathrin perturbation affects 
clathrin vesicle formation. (C) Western blots of clathrin-coated vesicle 
isolation fractions from PC12 cells stably expressing mCherry-FKBP-
CLC treated for 2 h with either vehicle control (lanes 1–6) or the drug 
AP20187 to perturb clathrin function (lanes 7–12). (D) Densitometry 
quantification of CCV fraction from three biological replicates each 
with at least two technical replicates of clathrin coated–vesicle 
isolations in PC12 cells stably expressing mCh-FKBP-CLC and treated 
for 2 h with either vehicle control or AP20187 to acutely perturb 
clathrin function. AP-3 subunits display significantly higher signals in 
CCV fractions from AP20187-treated cells compared with vehicle 
control–treated cells despite decreases in other adaptor subunits like 
AP-1 G and AP-2 A. The extent of decrease in AP-1 G and AP-2 A in 
CCV fraction treated with AP20187 compared with control is similar, 
as highlighted by the nonsignificance when these two are compared 
(not significant [NS]). CCV, clathrin-coated vesicle fraction; H, 
homogenate; IB, immunoblot; P1, pellet 1; P2, pellet 2; S1, 
supernatant 1; S2, supernatant 2; p values, analysis of variance 
multiple comparisons with Student–Newman–Keuls post hoc test.
FIGURE 4: Model of acute pharmacological perturbation to clathrin 
and AP-3 in PC12 cells stably expressing mCh-FKBP-CLC. Step 1: AP-2 
vesicles bud from the plasma membrane (PM) in a clathrin-dependent 
manner. Acute AP20187 treatment perturbs FKBP-CLC, and thus 
clathrin function, in these cells. AP-2-clathrin coated vesicles (CCV) 
feed into endosomal organelles. Step 2: AP-3 vesicles, presumably 
coated with clathrin, bud from an early endosomal compartment to 
form SLMVs. Acute treatment of these cells with brefeldin A disrupts 
AP-3 vesicle formation. We tested whether acute treatment of these 
cells with AP20187 similarly affects SLMV formation. We hypothesized 
that if clathrin is required for AP-3–derived SLMV formation, then 
AP20187 treatment after release of a brefeldin A block in SLMV 
formation should further prohibit SLMV formation.
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principal component analysis of multiple 
datasets (Borner et al., 2006, 2012). AP-1 
and AP-2 faithfully cosegregate with clath-
rin-coated vesicles in both approaches. 
These assays provide different answers, 
however, as to whether AP-3 resides in 
clathrin-coated vesicles (Borner et al., 2006, 
2012). Comparison of control and clathrin-
knockdown cells by quantitative mass spec-
trometry suggests that AP-3 would reside in 
these organelles, a result that we recapitu-
lated here. However, similar to principal 
component analysis of clathrin-coated vesi-
cle fractions, we also observed a discrep-
ancy in cosedimentation of AP-3 with clath-
rin-coated vesicle fractions. In our case, 
there is a drastic difference between chronic 
and acute clathrin function perturbation de-
spite consistent behavior by AP-1 and AP-2 
adaptors. This suggests that AP-3 cosedi-
ments with clathrin-coated vesicles but in 
membranous organelles distinct from these 
caged vesicles. Second, it implies that the 
sensitivity of AP-3 to long-term clathrin RNA 
interference results from indirect effects of 
chronic perturbations in the endocytic path-
way. The “anomalous” AP-3 behavior 
prompted us to reevaluate whether AP-3 in-
deed requires clathrin to generate vesicles 
and whether clathrin–AP-3 interactions fol-
low principles similar to those by adaptors 
AP-1 and AP-2.
Our findings in PC12 cells indicate that 
acute perturbation of clathrin with a mCh-
FKBP-CLC chimera does not prevent the 
formation of AP-3 vesicles from endosomes 
after a brefeldin A block. We interpreted 
this observation as evidence of clathrin dispensability in AP-3 SLMV 
budding from endosomes. We examined alternative interpretations 
that could also explain our brefeldin A-AP20187 pharmacological 
epistasis results. We asked 1) whether AP-3 interacts and colocalizes 
with mCh-FKBP-CLC in endosomes, which gives rise to AP-3-de-
rived vesicles; 2) whether there is biological activity for the clathrin 
light-chain chimera in PC12 cells, which we demonstrated by deple-
tion of AP-1, AP-2, and synaptic vesicle cargoes from clathrin-coated 
vesicle fractions after acute AP20187 treatment; and 3) whether 
there is an alternative, “clathrin-like” molecule taking the place of 
clathrin heavy chain. AP-3 coprecipitates with the clathrin heavy 
chain encoded in human chromosome 22 (Liu et al., 2001). We esti-
mate, however, that a role of this clathrin isoform is a remote option. 
Rodent cells do not express chromosome 22 clathrin, and our func-
tional assessment of a clathrin-AP-3 interaction was conducted in 
rat PC12 cells (Wakeham et al., 2005). Thus a simple interpretation 
of our data is that the clathrin interaction with AP-3 is not required 
for vesicle budding from endosomes. This conclusion is in rapport 
with previous studies in which AP-3 function is restored in B3 mutant 
cells by expression of recombinant B3 chains carrying a defective 
clathrin-binding motif defined in vitro and presumed to be unique 
in AP-3 (Peden et al., 2002). The present conclusion is also consis-
tent with our past studies in cell-free vesicle reconstitution experi-
ments. Cell-free AP-3 budding is resistant to cytosolic clathrin de-
pletion. Moreover, de novo vesicle formation from endosomes is 
the levels of S3 adaptin precipitated by D antibodies as indications 
of reassembled AP-3 complexes with different recombinant B3A 
subunits (Di Pietro et al., 2006; Salazar et al., 2006, 2009; Gokhale 
et al., 2012). The content of clathrin precipitating with D adaptin 
antibodies increased in all Ap3b1pe/pe cells where AP-3 complexes 
were reassembled by reexpression of recombinant B3A chains 
(Figure 7, compare lane 2 with lanes 4, 6, 8, and 10). Of importance, 
this increase in clathrin coprecipitation with reassembled AP-3 
complexes was not sensitive to any of the mutations ablating puta-
tive clathrin-binding determinants in the B3A hinge-ear domain. 
These results indicate that the B3A hinge-ear domain is not neces-
sary for clathrin interactions with cross-linked AP-3 complexes. Our 
results suggest that AP-3 diverges from the model by which AP-1 
and AP-2 adaptors bind to clathrin cages for vesicle biogenesis via 
the C-terminus of B adaptins with the terminal domain of clathrin-
heavy chain (Lemmon and Traub, 2012)
DISCUSSION
We explored the role of clathrin in AP-3–dependent vesicle budding 
by means of long-term clathrin shRNA down-regulation and rapid 
chemical-genetic perturbation of clathrin function. Down-regulation 
of clathrin heavy chain has been used to assess whether compo-
nents enriched in clathrin-coated vesicle fractions truly reside in 
these organelles. This approach has been validated in HeLa cells 
using quantitative mass spectrometry alone or in combination with 
FIGURE 6: Acute perturbation of clathrin function does not prohibit synaptic-like microvesicle 
formation after release of a brefeldin A block. PC12 cells stably expressing mCh-FKBP-CLC were 
treated for 2 h with brefeldin A (BFA) or vehicle control (EtOH) at 37°C. After this 2-h treatment, 
BFA-treated cells were either transferred to 4°C (BFA) or extensively washed at 4°C and then 
incubated with AP21087 (BFA-AP20187) or vehicle control (BFA-EtOH) for additional 2 h at 
37°C. SLMVs sediment to the middle of 5–20% glycerol velocity gradients. Fractions from this 
gradient were loaded onto SDS–polyacrylamide gels for Western blot and densitometry 
quantifications. Immunoblot (IB) for SV2 and VAMP7 was used to track SLMVs. (A, A`) 
Densitometry quantification of fraction signal per total signal in BFA-treated cells (white circles) 
as compared with EtOH-only treated cells (black circles). (B, B`) Densitometry quantification of 
fraction signal per total signal in BFA-EtOH–treated cells (black circles). (C, C`) Densitometry 
quantification of fraction signal per total signal in BFA-treated cells (white circles) as compared 
with BFA-AP20187–treated cells (black circles). (D, E) Western blot of VAMP7 and SV2, 
respectively, from EtOH-, BFA-, BFA-EtOH–, and BFA-AP20187–treated cells.
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of clathrin to antibody–magnetic beads complexes. An equally strik-
ing finding is the observation that Ap3b1pe/pe rescued with a recom-
binant B3A carrying a truncation of the entire B3A hinge-ear domain 
(B3A807Stop) still coprecipitates clathrin. These observations are 
consistent with a model by which either D-S3 adaptor hemicom-
plexes or AP-3 complexes lacking the ear domain associate to clath-
rin, directly or indirectly. This would represent a departure of the 
model by which canonical AP-1 and AP-2 adaptors productively en-
gage clathrin cages for vesicle biogenesis via the C-terminus of B 
adaptins with the terminal domain of clathrin heavy chain (Edeling 
et al., 2006; Knuehl et al., 2006; Schmid et al., 2006; Lemmon and 
Traub, 2012). Although clathrin binds preponderantly to the C-ter-
minus of B2 adaptin, two-hybrid evidence suggests a putative inter-
action between clathrin and the C-terminal domain of A adaptin 
(Knuehl et al., 2006). However, the functional relevance of the ap-
pendage domain of A adaptin has been tested, and it is dispensable 
(Motley et al., 2006). In fact, the A adaptin down-regulation pheno-
type can be fully rescued by expression of A adaptin lacking its 
appendage domain (Motley et al., 2006). In contrast, the D allele 
Ap3d1mh2j/mh2j, which lacks the appendage domain of D adaptin, 
possesses phenotypes indicating that the D appendage is not 
dispensable (Kantheti et al., 2003). Collectively, the evidence sup-
ports our contention that clathrin-AP-3 interactions differ from those 
between clathrin and the adaptor complexes AP-1 and AP-2.
A question that arises from our data concerns the extent to which 
the functionality of a clathrin–AP-3 association observed in PC12 
SLMV budding from endosomes reflects other putative AP-3–de-
pendent budding events. Nearly 40% of all AP-3 immunoreactivity 
in cells is present in endosomes (Peden et al., 2004; Theos et al., 
2005). A similar amount of AP-3, however, associates to tubules/
vesicles not identified as endosomes, and 4–9% associates with the 
trans-Golgi network (Peden et al., 2004; Theos et al., 2005). This 
leaves open the possibility that there may be additional modalities 
of AP-3-dependent budding distinct from vesicle generation from 
endosomes, such as the formation of large, dense secretory vesicles 
from the Golgi complex (Asensio et al., 2010), where AP-3 and clath-
rin may interact in a productive manner.
MATERIALS AND METHODS
Antibodies and constructs
Anti–clathrin heavy chain was purchased from EMD Millipore 
(Billerica, MA; CP45, clone: X22) and BD Transduction Laboratories 
(Pasadena, CA; 610499). Anti–clathrin light chain was purchased 
from EMD Millipore (AB9884) and Covance (Berkeley, CA; MMS-
423P, clone: CON.1). Anti–adaptin A (610501), anti–adaptin G 
(610385), and EEA1 (610456) were purchased from BD Transduction 
Laboratories. The AP3D SA4, c-myc 9E10, and SV2 10H antibodies, 
developed by Andrew Peden, J. Michael Bishop, and Kathleen M. 
Buckley, respectively, were obtained from the Developmental Stud-
ies Hybridoma Bank (University of Iowa, Department of Iowa City, IA). 
Anti-synaptophysin was purchased from EMD Millipore (MAB5258, 
clone: SY38). Anti-AP3B1 (13384-1-AP) and anti-pallidin (10891-1-
AP) were purchased from Protein Tech Group (Chicago, IL). Anti-
mCherry/DsRed was purchased from Clontech (Mountain View, CA; 
632496). Anti-GFP was purchased from AVES Labs (Tigard, OR; GFP-
1020). Antibodies directed against anti–muted, a kind gift from E. C. 
Dell’Angelica, AP-3 B-NAP, AP-3 S, and VAMP7 have been described 
(Larimore et al., 2011; Zlatic et al., 2011; Gokhale et al., 2012). Horse-
radish peroxidase–conjugated anti-mouse and anti-rabbit (A10668 
and G21234) and Alexa Fluor 488– and 555–conjugated anti-chicken 
(A11039), anti-mouse (A21121 and A21127), and anti-rabbit (A11034 
and A21429) were purchased from Invitrogen (Carlsbad, CA).
reconstituted with just recombinant ARF1 and purified AP-3. A vari-
able not controlled in these cell-free assays, however, is the contri-
bution of donor membrane–bound clathrin to the reaction (Faundez 
et al., 1997, 1998; Shi et al., 1998). The whole-cell approach using 
mCh-FKBP-CLC oligomerization and pharmacological epistasis 
overcomes this limitation and provides conclusive evidence that 
clathrin is dispensable for AP-3 vesicle formation from PC12 
endosomes.
If clathrin is unessential for AP-3 vesicle budding, then what roles 
may clathrin play? We postulate that an interaction between AP-3 
and clathrin reflects a scaffolding role such as Hrs-clathrin patches, 
clathrin-sorting nexin interactions, or clathrin organization of the ki-
netochore microtubules (Raiborg et al., 2001; McGough and Cullen, 
2012; Royle, 2012). Alternatively, clathrin binding to AP-3 could be 
a mechanism to deliver clathrin directionally by motors either in the 
absence or presence of vesicle membranes. Although we know of 
motors that bind to AP-1 and AP-3 adaptors directly (Nakagawa 
et al., 2000; Azevedo et al., 2009; Delevoye et al., 2009), there is no 
reported motor that binds to clathrin cages directly. In contrast, 
clathrin binds to dynein by means of an intervening protein, bicau-
dal D. This motor–clathrin association is necessary for normal neu-
rotransmission in Drosophila (Li et al., 2010). These nonbudding 
models predict that the stoichiometry of AP-3 and clathrin interac-
tions or the mode of binding between AP-3 and clathrin would differ 
from AP-1 and AP-2 interactions with clathrin cages. We indirectly 
tested the second prediction in fibroblasts carrying the B3A muta-
tion pearl (Ap3b1pe/pe; Peden et al., 2002). These Ap3b1pe/pe cells 
possess low levels of D-S3 adaptor hemicomplexes that we found 
coprecipitated clathrin. This association is specific, as experiments 
in mocha Ap3d1mh/mh cells, which lack D adaptin, are free of clathrin 
in these cross-linked precipitates, thus excluding spurious binding 
FIGURE 7: The clathrin-binding box of AP-3 B1 is dispensable for 
AP-3–clathrin coisolation. Pearl (Ap3b1pe/pe) fibroblasts or Pearl 
fibroblasts rescued with full-length Ap3b1 (pB3A), Ap3b1 containing a 
triple-alanine mutation in the clathrin box (pB3A871AAA), a deletion of 
the clathrin box in Ap3b1 (pB3A$ 807-831), or a truncation of Ap3b1 
eliminating the entire ear domain containing the clathrin box 
(pB3A807Stop) were treated with the cross-linker DSP. Lysates were 
subjected to coimmunomagnetic isolations directed against AP-3 D 
(lanes 1–10). All rescue lysates from DSP-treated cells show increased 
coisolation of clathrin heavy chain (immunoblot [IB]; clathrin lanes 4, 6, 
8, and 10) compared with unrescued lysate treated with DSP (IB, 
clathrin lane 2). Input represents 5% of immunomagnetic isolation 
load (lanes 11–15).
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Brefeldin A/AP20187 treatment followed by synaptic-like 
microvesicle fractionation
PC12 cells expressing mCh-FKBP-CLC were grown to confluence in 
10-cm plates, moved to an ice bath at 4°C, and washed three times 
in ice-cold phosphate-buffered saline (PBS)/1 mM MgCl2/0.1 mM 
CaCl2. Sequential drug–treated cells were incubated with warm 
DMEM supplemented with 10 mg/ml brefeldin A (Epicentre Bio-
technologies, Madison, WI) for 2 h at 37°C. Plates were then moved 
to an ice bath at 4°C and washed for 5 min with ice-cold DMEM 
three times. Cells were then incubated with ice-cold DMEM supple-
mented with either 50 nM AP20187 or 0.05% ethanol vehicle con-
trol for 15 min on an ice bath at 4°C to allow for drug equilibration. 
Cells were then moved to 37°C water bath for 10 min to quickly 
warm media and then to 37°C incubator for 2 h. Single drug–treated 
cells were incubated with warm DMEM supplemented with 10 mg/ml 
brefeldin A or 1% ethanol vehicle control for 2 or 4 h at 37°C. After 
incubation, cells were placed directly on an ice bath at 4°C and 
washed two times with ice-cold PBS/1 mM MgCl2/0.1 mM CaCl2 
with subsequent synaptic-like microvesicle fractionation.
Synaptic-like microvesicle fractionation was performed as previ-
ously described (Faundez et al., 1997; Faundez and Kelly, 2000; 
Clift-O’Grady et al., 1998). Briefly, cells were lifted in intracellular 
buffer (38 mM potassium aspartate, 38 mM potassium glutamate, 
38 mM potassium gluconate, 20 mM 3-(N-morpholino)propanesul-
fonic acid–KOH, pH 7.2, 5 mM reduced glutathione, 5 mM sodium 
carbonate, 2.5 mM magnesium sulfate, 2 mM ethylene glycol tet-
raacetic acid) and sedimented for 5 min at 800 × g at 4°C in a table-
top centrifuge. Cell pellet was suspended in 300 µl of Intracellular 
buffer supplemented with Complete antiprotease (Roche, Indianap-
olis, IN). Homogenate was prepared with a 12-µm clearance cell 
cracker with intracellular buffer supplemented with Complete anti-
protease at 4°C. Equal protein load from homogenate was centri-
fuged at 1000 × g for 5 min at 4°C in a table-top centrifuge, gener-
ating the first supernatant (S1) and pellet (P1). S1 was centrifuged at 
27,000 × g for 35 min at 4°C in a Sorvall SS34 rotor (Thermo Scien-
tific, Waltham, MA) to generate the second supernatant (S2) and 
pellet (P2). Equal volumes of the S2 were overlaid on a 5–25% glyc-
erol gradient prepared in intracellular buffer generated by a Bio-
comp Gradient Master (Biocomp, Fredericton, Canada). Gradients 
were then centrifuged at 218,000 × g for 75 min at 4°C in a Beck-
man SW55 rotor (Beckman Coulter, Palo Alto, CA). Aliquots of the 
glycerol gradient after centrifugation were analyzed by Western blot 
on 4–20% Criterion polyacrylamide gels (Bio-Rad).
Immunofluorescence, microscopy, and analysis
Coverslips were prepared as previously described (Craige et al., 
2008; Zlatic et al., 2011). Cells were seated to Matrigel-coated (BD 
Bioscience, San Jose, CA) coverslips. Cells were washed twice in 
PBS/1 mM MgCl2/0.1 mM CaCl2 and fixed with 4% paraformalde-
hyde in PBS. Cells were blocked, permeabilized, and probed with 
primary and secondary antibody in block buffer (PBS containing 
15% donor equine serum [HyClone], 2% bovine serum albumin 
[HyClone], 1% fish gelatin [Sigma-Aldrich, St. Louis, MO], and 0.02% 
saponin [Sigma-Aldrich]). After secondary antibody probing, cells 
were washed twice in block buffer and once with PBS supplemented 
with 1 mM MgCl2 and 0.1 mM CaCl2 and mounted on slides with 
Gelvatol.
Deconvolution microscopy was carried out as previously de-
scribed on a 200M inverted microscope (Carl Zeiss, Thornwood, NY) 
and Sedat filter set (Chroma Technology, Rockingham, UT) run with a 
multiwavelength, sequential capture, wide-field, three-dimensional 
microscopy system from SlideBook 4.0 OS X software (Intelligent 
Peptide directed against the AP3 D SA4 antibody antigen bind-
ing site (AQQVDIVTEEMPENALPSDEDDKDPNDPYRA) was ob-
tained from the Emory University Microchemical Facility (Atlanta, 
GA) and Invitrogen (EvoQuest Team, Carlsbad, CA).
Clathrin heavy chain (RHS39799577067) and muted 
(RHS397998822549) pLKO.1 shRNA constructs were purchased 
from Open Biosystems (Huntsville, AL). The constructs mCherry-
FKBP-CLC and EGFP-Rab5-Q79L have been described (Craige 
et al., 2008; Zlatic et al., 2011).
Cell culture, transfection, and infection
HEK293 and SH-SY5Y cells (American Type Culture Collection, 
Manassas, VA) cultured in DMEM (HyClone, Logan, UT) containing 
10% fetal bovine serum (HyClone) and 100 µg/ml penicillin and 
streptomycin (HyClone) and PC12 cells (American Type Culture 
Collection) cultured in DMEM containing 10% donor equine serum 
(HyClone), 5% fetal bovine serum, and 100 µg/ml penicillin and 
streptomycin were incubated at 37°C and 10% CO2. Generation 
and culture of Ap3b1pe/pe cells or Ap3b1pe/pe rescued with either 
recombinant wild-type B3A or B3A mutations ablating putative 
clathrin-binding determinants was as described (Peden et al., 
2002).
For transient transfections, HEK293 cells in wells of six-
well plates were incubated with 1 µg of DNA in OptiMEM (Life 
Technologies, Grand Island, NY) containing 0.5% Lipofectamine 
2000 (Invitrogen) for 4 h, followed by incubation with culture me-
dia. For stable transfections, PC12 cells were transfected as in 
transient transfections, followed by 0.2 mg/ml G418 (Invitrogen) 
drug selection. Selected cells were serially diluted, and clonal 
populations were maintained in PC12 culture media supple-
mented with 0.1 mg/ml G418.
For lentiviral infection, lentivirus containing shRNA constructs 
were prepared by the Emory University Viral Vector Core. 
Anti biotic-free culture medium containing 1 µl of high-titer lentivi-
rus was incubated with HEK293 or SH-SY5Y cells for 24 h, fol-
lowed by incubation for 6 d with culture medium supplemented 
with 0.1 mg/ml selection drug, hygromycin B (Invitrogen), in 
10-cm culture plates.
Acute clathrin perturbation and clathrin-coated vesicle 
fractionation
HEK293 or PC12 cells expressing the mCh-FKBP-CLC construct 
were grown to confluence. Cells were incubated for 2 h at culture 
conditions in medium supplemented with 50 nM AP20187 (B/B 
Homodimerizer 635060; Clontech) or 0.05% ethanol vehicle control 
(Zlatic et al., 2011). HEK293 cells infected with lentivirus containing 
scramble or clathrin heavy-chain shRNA constructs and transiently 
expressing mCh-FKBP-CLC, SH-SY5Y cells infected with lentivirus 
containing scramble or muted shRNA constructs, and PC12 cells 
stably expressing mCh-FKBP-CLC with acute clathrin perturbation 
were prepared for clathrin-coated vesicle fractionation as previously 
described (Girard et al., 2004). Fractions were analyzed by either 
Western blot or Coomassie staining of 4–20% Criterion polyacryl-
amide gels (Bio-Rad, Hercules, CA).
DSP cross-linking and immunomagnetic precipitation
HEK293 and PC12 cells expressing mCh-FKBP-CLC were prepared 
for DSP cross-linking, followed by immunomagnetic precipitation as 
previously described (Salazar et al., 2009; Zlatic et al., 2010, 2011; 
Gokhale et al., 2012; Perez-Cornejo et al., 2012). The resulting iso-
lated proteins were analyzed by Western blot of 4–20% Criterion 
polyacrylamide gels.
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Imaging Innovations, Denver, CO; Craige et al., 2008; Newell-Litwa 
et al., 2009; Zlatic et al., 2011). Samples were imaged with a 
100×/1.40 numerical aperture (NA) oil differential interference 
contrast objective (Carl Zeiss) and captured with a scientific-
grade, cooled, charge-coupled device (CCD) CoolSnap HQ camera 
(Photometrics, Tucson, AZ) run with an ORCA-ER chip (Hamamatsu 
Photonics, Hamamatsu, Japan). Out-of-focus light was removed us-
ing a nearest-neighbor constrained iterative deconvolution algorithm 
with Gaussian smoothing.
SIM microscopy was carried out using a Nikon N-SIM microscopy 
system on an Eclipse Ti inverted microscope run with Nikon Ele-
ments software (Nikon, Melville, NY). The samples were imaged 
with a 100–/1.49 NA objective and an iXon DU897 electron-multi-
plying CCD camera (Andor Technology, Belfast, Northern Ireland). 
Wide-field images were acquired with a mercury lamp and the 
appropriate filters: 480/30-nm excitation, 535/40-nm emission 
(Alexa 488) or 540/25-nm excitation, 692/68-nm emission (Alexa 
555). Wide-field images were deconvolved with Huygens software 
(Scientific Volume Imaging, Hilversum, Netherlands). SIM images 
were acquired with laser excitation and emission filters, 488-nm ex-
citation, 520/40-nm emission (Alexa 488) and 561-nm excitation, 
640/40-nm emission (Alexa 555). Images were acquired in three-
dimensional SIM mode (for each SIM image 15 images with five 
different phases of three different angular orientations of illumina-
tion were collected), and z-stacks were collected for each image. 
SIM images were processed with Nikon Elements software.
Three-dimensional surface reconstruction was carried out with 
Imaris 6.3.1 software (Bitplane, St. Paul, MN) from SIM and decon-
volution image z-stacks. Whole-cell and profile colocalization, pro-
file perimeter, and total fluorophore pixel content were determined 
from three z-plane focal slices per region of interest and carried out 
with MetaMorph 6.1 software (Universal Imaging, Sunnyvale, CA) 
with manual thresholding.
Statistical analysis
Experimental conditions were compared using Synergy Kaleida-
Graph, version 4.1.3 (Reading, PA), or StatPlus Mac Built5.6.0pre/
Universal (AnalystSoft, Vancouver, Canada). Data are presented as 
boxplots displaying the four quartiles of the data, with the “box” 
comprising the two middle quartiles, separated by the median. The 
upper and lower quartiles are represented by the single lines ex-
tending from the box.
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